{
  "questionnaire": {
    "title": "irAKI vs Other AKI Classification Assessment",
    "description": "Comprehensive clinical assessment to distinguish immune-related acute kidney injury from other AKI etiologies",
    "version": "1.0",
    "reference": "Based on Sprangers et al. Nature Reviews Nephrology 2022 and clinical guidelines",
    "scale": {
      "type": "9-point Likert",
      "range": "1-9",
      "anchors": {
        "1": "Strongly disagree / Very unlikely",
        "5": "Neutral / Uncertain",
        "9": "Strongly agree / Very likely"
      }
    },
    "questions": [
      {
        "id": "Q1",
        "category": "temporal_relationship",
        "question": "The temporal relationship between immune checkpoint inhibitor (ICI) exposure and AKI onset strongly supports irAKI diagnosis",
        "description": "Assess the timing of AKI development in relation to ICI therapy initiation/continuation",
        "clinical_context": {
          "supportive_evidence": [
            "AKI onset 2-5 months after ICI initiation",
            "Clear temporal sequence without other explanations",
            "AKI development during active ICI treatment",
            "No alternative temporal associations"
          ],
          "contradictory_evidence": [
            "AKI onset before ICI therapy",
            "AKI onset >12 months after ICI discontinuation",
            "Clear alternative temporal cause identified",
            "AKI pattern inconsistent with typical irAKI timeline"
          ]
        },
        "specialty_focus": {
          "medical_oncology": "ICI treatment timeline and dosing history",
          "nephrology": "AKI progression pattern and timing",
          "clinical_pharmacy": "Drug exposure timeline analysis"
        }
      },
      {
        "id": "Q2",
        "category": "prerenal_exclusion",
        "question": "Prerenal causes of AKI have been adequately excluded",
        "description": "Evaluate whether volume depletion, hypotension, or reduced effective circulating volume explains the AKI",
        "clinical_context": {
          "assessment_criteria": [
            "Hemodynamic stability assessment",
            "Volume status evaluation",
            "Response to fluid resuscitation",
            "Fractional excretion of sodium/urea",
            "Medication effects on renal perfusion"
          ],
          "exclusion_evidence": [
            "Normal hemodynamics and volume status",
            "Lack of response to appropriate fluid resuscitation",
            "FENa >1% or FeUrea >35%",
            "No nephrotoxic hemodynamic medications"
          ]
        },
        "specialty_focus": {
          "critical_care": "Hemodynamic assessment and fluid status",
          "nephrology": "Renal perfusion and prerenal markers",
          "hospital_medicine": "Clinical volume assessment"
        }
      },
      {
        "id": "Q3",
        "category": "postrenal_exclusion",
        "question": "Postrenal/obstructive causes of AKI have been adequately excluded",
        "description": "Assess whether urinary tract obstruction or structural abnormalities explain the AKI",
        "clinical_context": {
          "assessment_criteria": [
            "Renal ultrasound findings",
            "CT imaging if indicated",
            "Bladder catheter drainage response",
            "Post-void residual assessment",
            "Urological evaluation if appropriate"
          ],
          "exclusion_evidence": [
            "Normal renal ultrasound without hydronephrosis",
            "No evidence of structural obstruction",
            "Normal bladder emptying",
            "No retroperitoneal pathology"
          ]
        },
        "specialty_focus": {
          "nephrology": "Structural kidney assessment",
          "emergency_medicine": "Rapid obstruction exclusion",
          "clinical_informatics": "Imaging data interpretation"
        }
      },
      {
        "id": "Q4",
        "category": "other_intrinsic_exclusion",
        "question": "Other intrinsic causes of AKI (ATN, contrast nephropathy, other drugs) have been adequately excluded",
        "description": "Evaluate alternative intrinsic kidney injury mechanisms beyond immune-mediated causes",
        "clinical_context": {
          "alternative_causes": [
            "Acute tubular necrosis from hypotension/sepsis",
            "Contrast-induced nephropathy",
            "Other nephrotoxic medications",
            "Rhabdomyolysis or tumor lysis syndrome",
            "Thrombotic microangiopathy"
          ],
          "exclusion_criteria": [
            "No significant hypotensive episodes",
            "No recent contrast exposure",
            "Careful medication review excludes other nephrotoxins",
            "No evidence of muscle breakdown or hemolysis",
            "Normal peripheral blood smear"
          ]
        },
        "specialty_focus": {
          "nephrology": "Comprehensive AKI differential diagnosis",
          "clinical_pharmacy": "Nephrotoxic medication assessment",
          "critical_care": "Sepsis and hypotension-related AKI"
        }
      },
      {
        "id": "Q5",
        "category": "urinalysis_pattern",
        "question": "Urinalysis findings are consistent with immune-mediated kidney injury",
        "description": "Assess urinalysis pattern for findings suggestive of tubulointerstitial nephritis or immune injury",
        "clinical_context": {
          "supportive_findings": [
            "Proteinuria (typically <3g/day)",
            "Microscopic hematuria",
            "Pyuria without bacterial infection",
            "White blood cell casts",
            "Eosinophiluria (if present)",
            "Granular casts"
          ],
          "atypical_findings": [
            "Massive proteinuria (>3g/day)",
            "Red blood cell casts (suggests glomerular disease)",
            "No inflammatory cells",
            "Normal urinalysis despite significant AKI"
          ]
        },
        "specialty_focus": {
          "nephrology": "Urinalysis pattern interpretation",
          "renal_pathology": "Urinary sediment correlation with histology",
          "oncology_nursing": "Urinalysis monitoring in irAE assessment"
        }
      },
      {
        "id": "Q6",
        "category": "systemic_immune_activation",
        "question": "Laboratory evidence suggests systemic immune activation consistent with irAKI",
        "description": "Evaluate biomarkers and laboratory findings indicative of immune system activation",
        "clinical_context": {
          "supportive_markers": [
            "Peripheral eosinophilia (>4%)",
            "Elevated inflammatory markers (CRP, ESR)",
            "Complement consumption (low C3/C4)",
            "Elevated cytokines if measured",
            "Other organ irAE manifestations"
          ],
          "assessment_considerations": [
            "Eosinophil count trend over time",
            "Inflammatory marker correlation with AKI timing",
            "Complement levels compared to baseline",
            "Systemic vs localized inflammatory response"
          ]
        },
        "specialty_focus": {
          "rheumatology": "Immune activation markers and complement",
          "clinical_informatics": "Biomarker pattern analysis",
          "medical_oncology": "irAE-associated laboratory patterns"
        }
      },
      {
        "id": "Q7",
        "category": "concomitant_medications",
        "question": "Concomitant medications known to cause AKI/ATIN have been adequately assessed and excluded",
        "description": "Evaluate exposure to medications commonly associated with acute tubulointerstitial nephritis",
        "clinical_context": {
          "high_risk_medications": [
            "Proton pump inhibitors (PPIs)",
            "NSAIDs (including selective COX-2 inhibitors)",
            "Antibiotics (especially beta-lactams, sulfonamides)",
            "Diuretics and ACE inhibitors",
            "Other immunosuppressive agents"
          ],
          "assessment_approach": [
            "Comprehensive medication reconciliation",
            "Temporal relationship analysis for each medication",
            "Dose and duration assessment",
            "Previous tolerance to these medications",
            "Response to medication discontinuation"
          ]
        },
        "specialty_focus": {
          "clinical_pharmacy": "Comprehensive medication analysis",
          "hospitalist": "Medication reconciliation and assessment",
          "nephrology": "Drug-induced nephritis patterns"
        }
      },
      {
        "id": "Q8",
        "category": "other_irae_correlation",
        "question": "The presence of other immune-related adverse events (irAEs) supports the diagnosis of irAKI",
        "description": "Assess whether concurrent or previous irAEs support immune-mediated etiology",
        "clinical_context": {
          "relevant_iraes": [
            "Dermatologic irAEs (rash, vitiligo)",
            "Gastrointestinal irAEs (colitis, hepatitis)",
            "Endocrine irAEs (thyroiditis, hypophysitis)",
            "Pulmonary irAEs (pneumonitis)",
            "Rheumatologic irAEs (arthritis, myositis)"
          ],
          "correlation_factors": [
            "Temporal clustering of multiple irAEs",
            "Response pattern to immunosuppression",
            "Shared immune-mediated mechanisms",
            "Severity correlation across organ systems"
          ]
        },
        "specialty_focus": {
          "medical_oncology": "irAE pattern recognition and correlation",
          "rheumatology": "Multi-organ autoimmune manifestations",
          "oncology_nursing": "irAE monitoring and documentation"
        }
      },
      {
        "id": "Q9",
        "category": "biopsy_indication",
        "question": "Kidney biopsy is indicated and expected to show findings consistent with immune-mediated injury",
        "description": "Assess the appropriateness and expected yield of kidney biopsy for confirming irAKI",
        "clinical_context": {
          "biopsy_indications": [
            "AKI stage 2 or higher without clear alternative cause",
            "Atypical presentation requiring tissue diagnosis",
            "Need to exclude other glomerular diseases",
            "Persistent AKI despite initial management",
            "Unusual urinalysis findings"
          ],
          "expected_findings": [
            "Acute tubulointerstitial nephritis (most common)",
            "Lymphocytic infiltrate in interstitium",
            "Tubular epithelial damage",
            "Possible eosinophil infiltration",
            "Minimal glomerular involvement"
          ]
        },
        "specialty_focus": {
          "nephrology": "Biopsy indication assessment",
          "renal_pathology": "Expected histologic patterns in irAKI",
          "medical_oncology": "Risk-benefit of biopsy in cancer patients"
        }
      },
      {
        "id": "Q10",
        "category": "treatment_response",
        "question": "The clinical course and expected response pattern are consistent with irAKI",
        "description": "Evaluate whether the natural history and treatment response support immune-mediated etiology",
        "clinical_context": {
          "typical_course": [
            "Subacute onset over days to weeks",
            "Progressive worsening without intervention",
            "Response to corticosteroid therapy",
            "Improvement with ICI discontinuation",
            "Potential for recurrence with rechallenge"
          ],
          "response_indicators": [
            "Creatinine improvement with steroids",
            "Resolution of urinalysis abnormalities",
            "Improvement in other concurrent irAEs",
            "Appropriate timeline for recovery"
          ]
        },
        "specialty_focus": {
          "nephrology": "AKI recovery patterns and steroid response",
          "medical_oncology": "irAE treatment response patterns",
          "critical_care": "Clinical course in critically ill patients"
        }
      },
      {
        "id": "Q11",
        "category": "alternative_diagnosis_exclusion",
        "question": "Alternative specific diagnoses for AKI have been systematically excluded",
        "description": "Comprehensive assessment excluding other specific causes of AKI in this clinical context",
        "clinical_context": {
          "specific_alternatives": [
            "Cancer-related AKI (tumor lysis, obstruction)",
            "Infection-related AKI (sepsis, direct infection)",
            "Chemotherapy-induced nephrotoxicity",
            "Autoimmune disease flare (lupus, vasculitis)",
            "Thrombotic microangiopathy",
            "Acute glomerulonephritis"
          ],
          "exclusion_workup": [
            "Infection markers and cultures",
            "Autoimmune serologies if indicated",
            "Complement levels and immune complexes",
            "Peripheral blood smear examination",
            "Cancer staging and complication assessment"
          ]
        },
        "specialty_focus": {
          "nephrology": "Systematic AKI differential diagnosis",
          "rheumatology": "Autoimmune disease exclusion",
          "medical_oncology": "Cancer-related AKI causes"
        }
      },
      {
        "id": "Q12",
        "category": "clinical_gestalt",
        "question": "Overall clinical judgment strongly favors irAKI as the most likely diagnosis",
        "description": "Integrative clinical assessment considering all available evidence",
        "clinical_context": {
          "integration_factors": [
            "Constellation of clinical findings",
            "Temporal relationships and timeline",
            "Response to interventions",
            "Exclusion of alternative diagnoses",
            "Consistency with known irAKI patterns",
            "Overall clinical coherence"
          ],
          "confidence_factors": [
            "Strength of supporting evidence",
            "Adequacy of alternative cause exclusion",
            "Quality and completeness of available data",
            "Consistency across clinical domains",
            "Alignment with published literature"
          ]
        },
        "specialty_focus": {
          "all_specialties": "Integrative clinical reasoning",
          "clinical_informatics": "Evidence synthesis and pattern recognition",
          "hospitalist": "Comprehensive case assessment"
        }
      }
    ],
    "scoring_guidelines": {
      "interpretation": {
        "1-3": "Evidence strongly against irAKI / Alternative diagnosis likely",
        "4-6": "Uncertain / Requires additional evaluation",
        "7-9": "Evidence strongly supports irAKI / High probability diagnosis"
      },
      "confidence_thresholds": {
        "high_confidence": "≥7 on ≥8 questions with no major contradictions",
        "moderate_confidence": "≥6 on most questions with some uncertainty",
        "low_confidence": "Mixed scores or insufficient evidence"
      },
      "consensus_calculation": {
        "method": "Weighted average with confidence adjustment",
        "minimum_agreement": "≥70% of experts within 2 points on final gestalt",
        "debate_threshold": "≥3 point disagreement on any question"
      }
    },
    "clinical_decision_support": {
      "high_probability_iraki": {
        "threshold": "≥7.0 average score",
        "recommendations": [
          "Consider kidney biopsy for confirmation",
          "Initiate corticosteroid therapy",
          "Hold or discontinue ICI therapy",
          "Monitor for other irAEs",
          "Nephrology consultation"
        ]
      },
      "moderate_probability_iraki": {
        "threshold": "5.0-6.9 average score",
        "recommendations": [
          "Kidney biopsy strongly recommended",
          "Exclude alternative causes more thoroughly",
          "Consider empiric steroid trial",
          "Multidisciplinary discussion",
          "Close monitoring with serial assessments"
        ]
      },
      "low_probability_iraki": {
        "threshold": "<5.0 average score",
        "recommendations": [
          "Focus on alternative AKI causes",
          "Standard AKI management",
          "Continue ICI if oncologically appropriate",
          "Consider irAKI if clinical course changes",
          "Document reasoning for alternative diagnosis"
        ]
      }
    }
  },
  "validation": {
    "content_validity": "Reviewed by multidisciplinary expert panel",
    "clinical_correlation": "Based on published irAKI case series and guidelines",
    "inter_rater_reliability": "Target >0.8 agreement among expert reviewers",
    "sensitivity_analysis": "Question weighting validation against clinical outcomes"
  }
}